Profile data is unavailable for this security.
About the company
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.
- Revenue in USD (TTM)9.16m
- Net income in USD-68.17m
- Incorporated2016
- Employees43.00
- LocationIkena Oncology Inc50 Northern Ave.BOSTON 02210United StatesUSA
- Phone+1 (857) 343-8292
- Fax+1 (302) 655-5049
- Websitehttps://www.ikenaoncology.com
More ▼
Mergers & acquisitions
| Acquired company | IKNA:NMQ since announced | Transaction value |
|---|---|---|
| Pionyr Immunotherapeutics Inc | -75.00% | 31.44m |
Data delayed at least 15 minutes, as of Apr 25 2024 15:41 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kezar Life Sciences Inc | 7.00m | -101.87m | 58.34m | 58.00 | -- | 0.311 | -- | 8.33 | -1.40 | -1.40 | 0.0965 | 2.58 | 0.0269 | -- | -- | 120,689.70 | -39.12 | -32.54 | -41.41 | -34.09 | -- | -- | -1,455.29 | -4,308.11 | -- | -- | 0.051 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Calcimedica Inc | 0.00 | -34.36m | 58.96m | 14.00 | -- | 3.83 | -- | -- | -26.09 | -26.09 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -132.51 | -63.99 | -155.72 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 59.09m | 134.00 | 4.99 | 0.2364 | 1.81 | 0.2294 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
| Correlate Energy Corp | 7.56m | -12.79m | 59.18m | 19.00 | -- | -- | -- | 7.82 | -0.3554 | -0.3554 | 0.21 | -0.0877 | 2.22 | -- | 13.19 | 398,051.60 | -375.16 | -315.47 | -- | -- | 18.27 | 15.42 | -169.09 | -201.03 | -- | -0.7239 | 8.30 | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 59.28m | 217.00 | -- | 0.4376 | -- | 18.65 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Rallybio Corp | 0.00 | -74.56m | 59.74m | 43.00 | -- | 0.5629 | -- | -- | -1.84 | -1.84 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -50.37 | -- | -54.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Mural Oncology PLC | 0.00 | -207.45m | 60.92m | 117.00 | -- | 0.2278 | -- | -- | -12.43 | -12.43 | 0.00 | 15.81 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.09m | 62.25m | 0.00 | -- | -- | -- | -- | -0.1205 | -0.1205 | 0.00 | -0.0797 | 0.00 | -- | -- | -- | -929,284.40 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -543.50 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Ikena Oncology Inc | 9.16m | -68.17m | 62.25m | 43.00 | -- | 0.3667 | -- | 6.80 | -1.63 | -1.63 | 0.2196 | 3.52 | 0.0503 | -- | -- | 213,046.50 | -37.42 | -29.72 | -41.48 | -34.62 | -- | -- | -744.09 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Moolec Science SA | 2.65m | -52.66m | 62.50m | 45.00 | -- | 6.17 | -- | 23.63 | -1.44 | -1.44 | 0.0766 | 0.2367 | -- | -- | -- | 58,780.00 | -- | -- | -- | -- | 2.92 | -- | -1,990.79 | -- | 0.2243 | -0.1889 | 0.2372 | -- | -- | -- | -1,044.02 | -- | -- | -- |
| Aligos Therapeutics Inc | 15.53m | -87.68m | 62.73m | 66.00 | -- | 0.6813 | -- | 4.04 | -1.82 | -1.82 | 0.3204 | 1.22 | 0.1041 | -- | -- | 235,287.90 | -58.80 | -51.20 | -72.71 | -59.73 | -- | -- | -564.61 | -1,399.21 | -- | -- | 0.0026 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Equillium Inc | 36.08m | -13.34m | 63.11m | 44.00 | -- | 2.80 | -- | 1.75 | -0.3845 | -0.3845 | 1.04 | 0.6403 | 0.5597 | -- | 10.98 | 820,090.90 | -20.68 | -46.81 | -38.46 | -57.36 | -- | -- | -36.96 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| VolitionRX Ltd | 775.30k | -35.32m | 65.65m | 110.00 | -- | -- | -- | 84.68 | -0.504 | -0.504 | 0.0109 | -0.0953 | 0.0335 | -- | 4.92 | 7,048.18 | -154.29 | -111.92 | -- | -196.20 | -- | -- | -4,601.71 | -10,793.31 | -- | -280.52 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -7.45m | 66.37m | 12.00 | -- | 3.89 | -- | -- | -0.5863 | -0.5863 | 0.00 | 1.31 | 0.00 | -- | -- | 0.00 | -82.73 | -- | -113.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
| Medicinova Inc | 1.00m | -8.57m | 66.46m | 13.00 | -- | 1.07 | -- | 66.46 | -0.1748 | -0.1748 | 0.0204 | 1.27 | 0.0142 | -- | -- | 76,923.08 | -12.21 | -15.36 | -12.80 | -15.90 | -- | -- | -857.15 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
Data as of Apr 25 2024. Currency figures normalised to Ikena Oncology Inc's reporting currency: US Dollar USD
33.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Dec 2023 | 4.77m | 9.88% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 4.18m | 8.67% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.72m | 3.56% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.50m | 3.12% |
| Verition Fund Management LLCas of 31 Dec 2023 | 1.32m | 2.74% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 999.51k | 2.07% |
| Geode Capital Management LLCas of 31 Dec 2023 | 529.37k | 1.10% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 410.75k | 0.85% |
| Laurion Capital Management LPas of 31 Dec 2023 | 372.61k | 0.77% |
| Vestal Point Capital LPas of 31 Dec 2023 | 322.67k | 0.67% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
